QR-koodi

Oncologic outcome and safety profile of first-line enfortumab vedotin plus pembrolizumab vs. conventional chemotherapy in advanced urothelial cancer

Aim: The aim of this multicenter study was to assess patient characteristics and short-term survival outcomes of first-line (1L) enfortumab vedotin plus pembrolizumab (EVP) as compared with conventional chemotherapy in locally advanced or metastatic urothelial carcinoma (la/mUC). Methods: The databa...

Täydet tiedot

Tallennettuna:
Päätekijät: Makito Miyake, Nobutaka Nishimura, Yuki Oda, Takuto Shimizu, Takeshi Inoue, Satoshi Anai, Keichi Sakamoto, Yoshiaki Matsumura, Yuta Toyoshima, Daiki Ichii, Kota Iida, Takashi Iwamoto, Norimi Takamatsu, Atsushi Tomioka, Hiroaki Yamamoto, Fumisato Maesaka, Kiyohide Fujimoto, on behalf of the Nara Urological Research Treatment Group
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Open Exploration Publishing Inc. 2026-07-01
Sarja:Exploration of Targeted Anti-tumor Therapy
Aiheet:
urothelial carcinoma
chemotherapy
response
outcome
enfortumab vedotin
pembrolizumab
adverse event
Linkit:https://www.explorationpub.com/uploads/Article/A1002379/1002379.pdf
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia